Peripartum cardiomyopathy is a heart failure syndrome occurring late in pregnancy or during the early post-natal period. The pathophysiology of peripartum cardiomyopathy is not fully understood and various mechanisms have been postulated including an underlying inflammatory process. We here report four cases presenting with acute left ventricular systolic dysfunction. Three out of four of the patients presented with a left ventricular ejection fraction <30% and one with a left ventricular ejection fraction of 35%. All made a full clinical recovery following treatment with high-dose intravenous steroids. This case series adds to the growing body of evidence for the role for immunosuppressants in the management of peripartum cardiomyopathy.
SlwaKHilfiker-KleinerDPetrieMC. Current state of knowledge on aetiology, diagnosis, management and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail2010; 12: 767–778.
2.
GouleyBAMcMillanTMBelletS. Idiopathic myocardial degeneration associated with pregnancy and especially the peripartum. Am J Med Sci1937; 19: 185–199.
3.
BrarSSKhanSSSandhuGK. Incidence, mortality and racial differences in peripartum cardiomyopathy. Am J Cardiol2007; 100: 302–304.
4.
DesaiDMoodleyJNaidooD. Peripartum cardiomyopathy: experiences at King Edward VII hospital, Durban, South Africa and a review of the literature. Trop Doct1995; 25: 118–123.
5.
FettJDChristieLGCarrawayRD. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc2005; 80: 1602–1606.
LamparterSPankuweitSMaischB. Clinical and immunologic characteristics in peripartum cardiomyopathy. Int J Cardiol2007; 118: 14–20.
10.
O’ConnellJBConstanzo-NordinMRSubramanianR. Peripartum cardiomyopathy: clinical haemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol1986; 8: 52–56.
11.
PyattJRDubeyG. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad Med J2011; 87: 34–39.
12.
MideiMGDeMentSHFeldmanAM. Peripartum myocarditis and cardiomyopathy. Circulation1990; 81: 922–928.
13.
BozkurtBVillaneuvaFSHolubkovR. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol1999; 34: 177–180.
14.
SliwaKSkudickyDBergemannA. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-I. J Am Coll Cardiol2000; 35: 701–705.
15.
ForsterOHilfiker-KleinerDAnsariAA. Reversal of IFN gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail2008; 10: 861–868.
16.
SliwaKForsterOLibhaberE. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J2006; 27: 441–446.
17.
SliwaKSkudickyDCandyG. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail2002; 4: 305–309.
18.
McNamaraDMHolubkovRStarlingRC. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation2001; 103: 2254–2259.
19.
MasonJWO'ConnellJBHerskowitzA. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med1995; 333: 269–275.
20.
DemakisJGRahimtoolaSHSuttonGC. Natural course of peripartum cardiomyopathy. Circulation1971; 44: 1053–1061.
21.
MuraliSBaldisseriMR. Peripartum cardiomyopathy. Crit Care Med2005; 33: S340–346.
